About
Immuno-oncology
Areas of Focus
Categories
Biologics & Biopharmaceutical
Team (7)
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
6
As Collaborator
1
Total Enrollment
479
By Phase
PHASE1/PHASE2: 4PHASE2: 1PHASE1: 2
By Status
RECRUITING: 3ACTIVE_NOT_RECRUITING: 2NOT_YET_RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT07018752Collaborator
A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
PHASE1/PHASE2Not yet recruiting
49 participants
Started: Aug 31, 2025 · Completed: Jan 31, 2030
NCT06887803Lead Sponsor
A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors
PHASE1/PHASE2Recruiting
26 participants
Started: May 31, 2025 · Completed: Jul 31, 2028
NCT06879717Lead Sponsor
A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients
PHASE1/PHASE2Recruiting
45 participants
Started: Apr 22, 2025 · Completed: Jan 31, 2028
NCT06717126Lead Sponsor
A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
PHASE2Recruiting
85 participants
Started: Feb 27, 2025 · Completed: Dec 31, 2028
NCT05586516Lead Sponsor
A Study to Assess an ATX Inhibitor (IOA-289) in Patients with Metastatic Pancreatic Cancer
PHASE1/PHASE2Active, not recruiting
24 participants
Started: Oct 10, 2022 · Completed: Mar 1, 2026
Locations (1)
Headquarters
Geneva, Switzerland
Map
Loading map...